{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:00Z","timestamp":1793398200162,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["1U01CA283931-01"],"award-info":[{"award-number":["1U01CA283931-01"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["K08 CA259536"],"award-info":[{"award-number":["K08 CA259536"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1053\/j.gastro.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:20:21Z","timestamp":1776244821000},"page":"1606-1615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review"],"prefix":"10.1053","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2740-8818","authenticated-orcid":false,"given":"Nicole E.","family":"Rich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2026.03.006_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2026.03.006_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.03.006_bib4","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"D'Souza","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.03.006_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/djad172","article-title":"Risk of hepatocellular carcinoma in people with HIV in the United States, 2001\u20132019","volume":"116","author":"McGee-Avila","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2026.03.006_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.30638","article-title":"Evaluation of a multifaceted intervention to reduce health disparities in hepatitis c screening: a pre-post analysis","volume":"70","author":"Jain","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2026.03.006_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib10","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/HEP.0000000000000860","article-title":"MASH clinical trials and drugs pipeline: an impending tsunami","volume":"82","author":"Noureddin","year":"2025","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib12","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.gastro.2026.03.006_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2214\/AJR.21.26735","article-title":"Associations of ultrasound LI-RADS visualization score with examination, sonographer, and radiologist factors: retrospective assessment in over 10,000 examinations","volume":"218","author":"Fetzer","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.gastro.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.03.006_bib16","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.03.006_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102755","article-title":"Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis","volume":"75","author":"Kao","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1053\/j.gastro.2026.03.006_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.30129","article-title":"Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial","volume":"69","author":"Singal","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cgh.2014.04.033","article-title":"Improved surveillance for hepatocellular carcinoma with a primary care\u2013oriented clinical reminder","volume":"13","author":"Beste","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib24","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.03.006_bib25","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.cgh.2020.09.014","article-title":"Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis","volume":"19","author":"Singal","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2023.07.018","article-title":"Financial burden of hepatocellular carcinoma screening in patients with cirrhosis","volume":"22","author":"Narasimman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000146","article-title":"Effectiveness of HCC surveillance programs using multitarget blood test: a modeling study","volume":"7","author":"Chhatwal","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2026.03.006_bib28","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.cgh.2018.12.005","article-title":"Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) algorithm in a cohort of veterans with cirrhosis","volume":"17","author":"Tayob","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"Johnson","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2026.03.006_bib30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients","volume":"14","author":"Berhane","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib31","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.14309\/ajg.0000000000003494","article-title":"Patient-perceived risk of hepatocellular carcinoma and net benefit of surveillance: a multicenter survey study","volume":"120","author":"Singal","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.03.006_bib32","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/HEP.0000000000001203","article-title":"Value of HCC surveillance in a landscape of emerging surveillance options: perspectives of a multi-stakeholder modified Delphi panel","volume":"82","author":"Singal","year":"2025","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-0042-1748924","article-title":"Biomarker development using liquid biopsy in hepatocellular carcinoma","volume":"42","author":"Grinspan","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2026.03.006_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000565","article-title":"National Liver Cancer Screening Trial (TRACER) study protocol","volume":"8","author":"Singal","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2026.03.006_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/apt.13841","article-title":"Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"45","author":"Simmons","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jmri.26835","article-title":"Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018","volume":"51","author":"Khatri","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"10.1053\/j.gastro.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2024.03.048","article-title":"Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC","volume":"81","author":"Kim","year":"2024","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/hep.30330","article-title":"Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2026.03.006_bib40","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1053\/j.gastro.2026.03.006_bib41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32434","article-title":"Risk factors for HCC in contemporary cohorts of patients with cirrhosis","volume":"77","author":"Kanwal","year":"2023","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2026.03.006_bib43","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41416-022-01851-1","article-title":"Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify","volume":"127","author":"Johnson","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2026.03.006_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","article-title":"Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis","volume":"78","author":"Nahon","year":"2023","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib46","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1016\/j.cgh.2023.04.019","article-title":"Risk stratification model for hepatocellular cancer in patients with cirrhosis","volume":"21","author":"Kanwal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-332034","article-title":"Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis","author":"El-Serag","year":"2024","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.03.006_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2023.02.022","article-title":"International Liver Cancer Association (ILCA) White Paper on hepatocellular carcinoma risk stratification and surveillance","volume":"79","author":"Singal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma","volume":"42","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib50","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.27016","article-title":"Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer","volume":"60","author":"Aleksandrova","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib51","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1158\/1055-9965.EPI-14-0161","article-title":"Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in Taiwan","volume":"23","author":"Chen","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2026.03.006_bib52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.23046","article-title":"Adipokines in liver diseases","volume":"50","author":"Marra","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.03.006_bib53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ijo.2017.187","article-title":"Abdominal fat deposits determined by magnetic resonance imaging in relation to leptin and vaspin levels as well as insulin resistance in the general adult population","volume":"42","author":"Genske","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2026.03.006_bib54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2026.03.006_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib56","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","article-title":"PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis","volume":"164","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.03.006_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282309","article-title":"Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score","volume":"18","author":"Thrift","year":"2023","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2026.03.006_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo4474","article-title":"Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease","volume":"14","author":"Fujiwara","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2026.03.006_bib59","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2026.03.006_bib60","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib61","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib62","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.03.006_bib63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2016.0086","article-title":"Risk score model for the development of hepatocellular carcinoma in treatment-na\u00efve patients receiving oral antiviral treatment for chronic hepatitis B","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib64","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2018.02.032","article-title":"Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B","volume":"69","author":"Hsu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib65","doi-asserted-by":"crossref","first-page":"92431","DOI":"10.18632\/oncotarget.21369","article-title":"Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2026.03.006_bib66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiz477","article-title":"Real-world effectiveness from the asia pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy","volume":"221","author":"Yang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2026.03.006_bib67","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0000000000001357","article-title":"Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir\/tenofovir","volume":"31","author":"Yu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib68","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1136\/gutjnl-2015-310818","article-title":"Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B","volume":"65","author":"Poh","year":"2016","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.03.006_bib69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2021.09.009","article-title":"Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States","volume":"76","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","article-title":"PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B","volume":"80","author":"Chun","year":"2024","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.03.006_bib71","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2023.11.005","article-title":"A liver stiffness-based etiology-independent machine learning algorithm to predict hepatocellular carcinoma","volume":"22","author":"Lin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852600243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852600243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:43:27Z","timestamp":1788295407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852600243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S001650852600243X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2026.03.006","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}